AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev plus Pemetrexed (pem) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx)

被引：23

作者：

Barlesi, F. ^{[1
]}

de Castro, J. ^{[2
]}

Dvornichenko, V. ^{[3
]}

Kim, J. H. ^{[4
]}

Pazzola, A. ^{[5
]}

Rittmeyer, A. ^{[6
]}

Vikstrom, A. ^{[7
]}

Mitchell, L. ^{[8
]}

Wong, E. K. ^{[8
]}

Gorbunova, V. ^{[9
]}

机构：

[1] Univ Mediterranee Assistance Publ Hop Marseille, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France

[2] La Paz Univ Hosp, Med Oncol Serv, Madrid, Spain

[3] SIHS Irkutsk Reg Oncol Ctr, Dept Oncol, Irkutsk, Russia

[4] Yonsei Canc Ctr, Dept Oncol, Seoul, South Korea

[5] Med Oncol Hosp SS Annunziata, Oncol Serv, Sassari, Italy

[6] Lungenfachklin Immenhausen, Dept Oncol, Immenhausen, Germany

[7] Linkoping Univ Hosp, Dept Pulm Med, S-58185 Linkoping, Sweden

[8] F Hoffmann La Roche Ltd, Global Med Affairs Dept, Basel, Switzerland

[9] NN Blokhin Canc Res Ctr Russia, Dept Hematol & Oncol, Moscow, Russia

来源：

关键词：

D O I：

10.1016/S0959-8049(11)70133-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

34LBA

引用

页码：16 / 16

页数：1